Liothyronine, Sodium

Phase 2Small molecule

IIpe, LLC

Liothyronine, Sodium is one of 130 small molecule programs targeting Hypothyroidism. It is currently in Phase 2.

Indications

Total Trials

Active Trials

129

Competitors

Pipeline

Status by Indication[3][1]

Indication

HypothyroidismActive, not recruiting

Coronary Artery BypassActive, not recruiting

Prostate CancerActive, not recruiting

Thyroid CancerActive, not recruiting

Multiple SclerosisActive, not recruiting

HypothyroidismPhase 2

Active, not recruiting

Coronary Artery BypassPreclinical

Active, not recruiting

Prostate CancerPhase 1

Active, not recruiting

Thyroid CancerPhase 2

Active, not recruiting

Multiple SclerosisPhase 1

Active, not recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Liothyronine, Sodium

IIpe, LLC

Phase 2

1 2

Mekinist

Novartis

Preclinical

3 3

Trexall

Alnylam Pharmaceuticals

Preclinical

—4

Viagra

VViatris Specialty LLC

Preclinical

1 5

Duragesic

CCephalon

Preclinical

1 6

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 7

Prednisone/prednisolone

Roche

Preclinical

3 8

Triptorelin Pamoate

Ipsen

Preclinical

2 9

Osmitrol

BB. Braun Medical Inc.

Preclinical

—10

Ifex

BBaxter Healthcare Corporation

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Thyroid Cancer2 trials

Azacitidine to Restore Thyroid Function in Patients With Persistent or Metastatic Thyroid Cancer

Completed·—·Phase 1·NCT00004062

A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Cell Origin

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01182285·13 enrolled

Hypothyroidism1 trial

A Study of T3 Therapy in Patients With Hypothyroidism

Completed·IIpe, LLC·Phase 2·NCT01800617·18 enrolled

Prostate Cancer1 trial

Gene Therapy and Radioactive Iodine in Treating Patients With Locally Recurrent Prostate Cancer That Did Not Respond to External-Beam Radiation Therapy

Terminated·MMayo Clinic·Phase 1·NCT00788307·8 enrolled

Multiple Sclerosis1 trial

Thyroid Hormone for Remyelination in Multiple Sclerosis (MS): A Safety and Dose Finding Study

Completed·OOregon Health and Science University·Phase 1·NCT02760056·15 enrolled

Coronary Artery Bypass1 trial

Peri-operative Oral Triiodothyronine Replacement Therapy to Decrease the Risk of Transient Atrial Fibrillation After Off-pump Coronary Artery Bypass Surgery

Completed·YYonsei University·N/A·NCT01153360·100 enrolled

1 more indication

AIN1 trial

A Study of Sustained-Release Liothyronine Sodium (T3) in Healthy Subjects

Completed·IIpe, LLC·Phase 1·NCT01581463·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Liothyronine, Sodium. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Liothyronine, Sodium compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Liothyronine, Sodium. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ipe, LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: IIpe, LLC

Liothyronine, Sodium

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Thyroid Cancer2 trials

Hypothyroidism1 trial

Prostate Cancer1 trial

Multiple Sclerosis1 trial

Coronary Artery Bypass1 trial

AIN1 trial

References

Drug Info

Quick Facts

Related News